OBJECTIVES The purpose of this study was to investigate the safety and efficacy of new-generation drug-eluting stents (DES) versus early-generation DES in women undergoing complex percutaneous coronary intervention (CPCI).
C ompared with bare-metal stents, the introduction of drug-eluting stents (DES) in clinical practice substantially improved the efficacy of percutaneous coronary intervention (PCI) by reducing the risk of in-stent restenosis and subsequent need of repeated revascularization (1) . However, important safety concerns arose with DES, mainly due to a lower thrombotic safety, especially with their unrestricted and off-label use (2) . In light of results from randomized controlled trials (RCTs), the U.S. (5) . Whereas men tend to have in general higher anatomic complexity, higher plaque burden, and more calcified lesions, women frequently have narrower, more tortuous vessels and more comorbidity at the time of coronary revascularization (6) (7) (8) . Therefore, the success and complication rates of PCI in women might not follow the same patterns as those in men. In fact, women have been reported to experience a significantly higher risk of coronary perforations, dissections, and access-site complications (7, 9, 10) . Additionally, female sex has been reported to be predictive of in-stent restenosis (11, 12) . All trials included in our analysis complied with the provisions of the Declaration of Helsinki, and the study protocols were approved by the institutional review board at each study center. All patients provided written informed consent for participation in each study. 
STUDY OBJECTIVES AND ENDPOINT DEFINITIONS.
The objectives of the current study were: 1) to characterize the effect of procedural complexity in women undergoing percutaneous revascularization; Giustino et al. Unadjusted and adjusted clinical outcomes according to complexity of PCI are reported in Figure 2 and Values are mean AE SD or n (%).
BMI ¼ body mass index; CABG ¼ coronary artery bypass graft; CAD ¼ coronary artery disease; DES ¼ drugeluting stent; IDDM ¼ insulin-dependent diabetes mellitus; MI ¼ myocardial infarction; NSTEMI ¼ non-ST-segment elevation myocardial infarction; PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-segment elevation myocardial infarction.
Giustino et al. 
EARLY-VERSUS NEW-GENERATION DES IN WOMEN
UNDERGOING CPCI. The 3-year outcomes according to PCI complexity and DES generation are reported in Figure 3 and Table 3 . In women who underwent CPCI, the use of new-generation DES was associated with a significantly lower risk of MACE at 3 years (adjusted HR: 0.81; 95% CI: 0.68 to 0.96) compared with earlygeneration DES ( Table 3) Table 2 ).
Landmark analysis in the time windows of 0 to 1 year and 1 to 3 years is illustrated in Figure 4 
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DES in Women Undergoing Complex PCI
A P R I L 1 1 , 2 0 1 6 : 6 7 4 -8 4 of off-label DES implantation compared with onlabel use or bare-metal stents (4, (16) (17) (18) . However, these studies were either observational in nature or had insufficient power to allow any definitive conclusions regarding the safety and efficacy of DES, especially in high-risk female patient subsets.
Considering the sex-specific substantial gap in knowledge, the present pooled database of female patients from 26 RCTs of DES was created (13,14) . In the present analysis, we sought to investigate the (25, 26) . As most of the stent-related thrombotic events occurred in the early phases, we cannot exclude that a customized approach to platelet inhibition with more potent agents administered early after PCI, followed by a switch to less potent agent or to a single antiplatelet agent, would provide improved net clinical benefit. However, irrespective of device generation, rates of MACE Values are n (%) unless otherwise indicated. *Log-rank p value. †Wald p value.
CI ¼ confidence interval; HR ¼ hazard ratio; MACE ¼ major adverse cardiac events; ST ¼ stent thrombosis; TLR ¼ target lesion revascularization; other abbreviations as in Table 1 . Abbreviations as in Tables 1 and 2 .
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